Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

UVAX 1197

Next Previous
Drug Profile

UVAX 1197

Alternative Names: UVAX-1197

Latest Information Update: 06 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator The Scripps Research Institute
  • Developer Uvax Bio
  • Class AIDS vaccines; Synthetic vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I HIV-1 infections

Most Recent Events

  • 21 Mar 2025 Uvax Bio completes the Phase-I clinical trials in HIV-1 infections (Prevention) in Australia (IM) (ACTRN12624000064505) (NCT06541093)
  • 30 Jan 2024 Phase-I clinical trials in HIV-1 infections (Prevention) in Australia (IM) (ACTRN12624000064505)
  • 19 Dec 2023 Uvax Bio plans a phase I trial for HIV-1 infections (Prevention) in Australia in January 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top